Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will intro... ...

President Donald Trump will announce on Tuesday that Pfizer plans to lower prices on several of its medications in the United States, a White House official said. ...

AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices. ...

Group 1: Dow Jones Index Performance - The Dow Jones Industrial Average increased by 3.9% in May, with 70% of its 30 constituent stocks ending the month positively [1] - The performance of the index was negatively impacted by two healthcare stocks, which were the worst performers in May [1] Group 2: UnitedHealth Group - UnitedHealth Group's shares fell by 26.6% in May due to multiple negative developments, including the sudden replacement of its CEO and the suspension of its earnings outlook for the year [3][5] - A criminal investigation by the Department of Justice for possible Medicare fraud and allegations of compromising patient health by incentivizing nursing homes contributed to the stock's decline [4] - The company aims to return to growth by 2026 but faces challenges in regaining investor confidence, with a year-to-date stock decline of 38% [5] Group 3: Merck - Merck's stock decreased by 9.8% in May, reaching a 52-week low of $73.31 per share, following an executive order from President Trump to lower prescription drug prices [6] - Concerns about Merck's future arose as analysts predicted a significant sales loss once its oncology drug Keytruda loses patent exclusivity, leading to a price target reduction from $115 to $84 per share [7] - Despite these challenges, Merck has a strong pipeline and is committed to dividend growth, currently yielding 3.9% [8]